A finding commonly observed in human immunodeficiency virus type 1 (HIV-1)-infected patients is invasion of the brain by activated T cells and infected macrophages, eventually leading to the development of neurological disorders and HIV-1-associated dementia. The recruitment of T cells and macrophages into the brain is likely the result of chemokine expression. Indeed, earlier studies revealed that levels of different chemokines were increased in the cerebrospinal fluid of HIV-1-infected patients whereas possible triggers and cellular sources for chemokine expression in the brain remain widely undefined. As previous studies indicated that HIV-1 Tat, the retroviral transactivator, is capable of inducing a variety of cellular genes, we investigated its capacity to induce production of chemokines in astrocytes. Herein, we demonstrate that HIV-1 Tat 72aa is a potent inducer of MCP-1, interleukin-8 (IL-8), and IP-10 expression in astrocytes. Levels of induced IP-10 protein were sufficiently high to induce chemotaxis of peripheral blood lymphocytes. In addition, Tat 72aa induced IL-8 expression in astrocytes. IL-8 mRNA induction was seen less then 1 h after Tat 72aa stimulation, and levels remained elevated for up to 24 h, leading to IL-8 protein production. Tat 72aa -mediated MCP-1 and IL-8 mRNA induction was susceptible to inhibition by the MEK1/2 inhibitor UO126 but was only modestly decreased by the inclusion of the p38 mitogen-activated protein kinase (MAPK) inhibitor SB202190. In contrast, Tat-mediated IP-10 mRNA induction was suppressed by SB202190 but not by the MEK1/2 inhibitor UO126. These findings indicate that MAPKs play a major role in Tat 72aa -mediated chemokine induction in astrocytes.
Human immunodeficiency virus type 1 (HIV-1) infection causes neurological disorders in up to 90% of infected patients, either by opportunistic infections of the brain (i.e., toxoplasmosis) or by development of HIV-1-associated dementia (HAD). HAD, a subcortical dementia characterized by cognitive deficits, as well as motor and behavioral impairment, occurs in up to 30% of all patients infected with HIV-1 (for reviews, see references 21 and 50). HAD develops independently of opportunistic infections and is caused by direct infection of cells in the central nervous system (CNS) by HIV-1. The main sources of infected cells in the brain are infiltrating macrophages and resident microglia cells (15, 32) . Besides the presence of infected cells in the brain, some characteristic findings in HAD patients include astrogliosis, microgliosis, the presence of activated T cells and macrophages in the brain, and the loss of specific neuronal populations (for reviews, see references 17, 21, and 50) .
A prerequisite for the recruitment of T cells and macrophages to the brain is the secretion of chemokines, small proteins of 5 to 12 kDa. Thus far, four major subfamilies of chemokines have been characterized (1, 5, 29, 30) . Of those, the CXC and CC chemokines are distinguished according to the position of the first two cysteines from four conserved cysteines linked by disulfide bonds. Those two cysteine residues are adjacent in CC chemokines, whereas they are separated by one amino acid in CXC chemokines. Gamma interferon (IFN-␥)-inducible protein 10 (IP-10) belongs to the family of CXC chemokines, along with monokine induced by IFN-␥ (Mig) and stromal cell-derived factor (SDF-1). IP-10 was first discovered as an IFN-␥-induced gene product found to be expressed in delayed-type hypersensitivity reactions of the skin (26) . In the human system, IP-10 is reported to attract NK cells, monocytes, and T lymphocytes (63) although some of the reported results are controversial (41, 52) . IL-8, the prototypic CXC chemokine, was initially described to be a monocyte-derived factor known to attract neutrophils (2) . Subsequently, T cells, neutrophils, fibroblasts, endothelial cells, and epithelial cells were also identified as sources for IL-8 production. IL-8 attracts T cells, neutrophils, basophils, and endothelial cells (for review, see reference 3). In addition, IL-8 mediates shear flow-resistant adhesion of monocytes (20) .
In recent publications, the role of chemokines in the development of HAD and the correlation between their presence in the cerebrospinal fluid (CSF) and the degree of neurological disorder observed in HIV-1-infected patients have been described. Fontana and coworkers reported that IP-10 is the only chemokine to be present in the CSF of all HIV-1-infected patients tested and is absent in uninfected control individuals (33) . Other groups demonstrated that expression of MCP-1 or RANTES in the CSF correlated with HIV-1 infection (7, 11, 13, 28) , with some of those studies having conflicting results. In addition, the chemokines MIP-1␣ and MIP-1␤ were detected in the brains of HIV-1 patients using in situ PCR (58) . For all of the above chemokines except IP-10, the cellular sources were identified as microglia and/or astrocytes. The cellular source of IP-10 in the brains of HAD patients has not been determined.
HIV-1 Tat, the retroviral transactivator, is essential for viral replication and directs viral gene expression by binding to the TAR element within the long terminal repeat of the integrated viral genome. HIV-1 Tat exists as different splice variants, of which Tat 72aa (one-exon Tat) and Tat 86aa or Tat 101aa (twoexon Tat) are the most prominent (31) . Tat can be released from HIV-1-infected cells (16) (39) , and induction of several cytokines or chemokines, such as tumor necrosis factor alpha (TNF-␣), interleukin-6 (IL-6), IL-8, and monocyte chemoattractant protein 1 (MCP-1) (10, 25, 36, 40, 49, 55, 67) . Putative receptors for Tat that would mediate the effects of extracellularly applied Tat include integrins and the CD26 molecule (22, 65) . In addition, Tat has been reported to be capable of penetrating the cell membrane without interacting with any receptor (59) .
In this study, we investigated the potential of HIV-1 Tat 72aa to stimulate chemokine expression in human astrocytes and demonstrated the involvement of the mitogen-activated protein kinase (MAPK) signaling pathway in Tat-mediated induction of MCP-1, IP-10, and IL-8 in human astrocytes.
MATERIALS AND METHODS
Reagents. The p38 MAPK inhibitor SB202190 and the MEK1/2 inhibitor UO126, as well as the respective controls SB202474 and UO124 were obtained from Calbiochem (San Diego, Calif.) and dissolved in dimethyl sulfoxide to achieve a stock concentration of 20 mM. HIV-1 Tat 72aa was produced as described earlier (14, 46) and was Ͼ98% pure. For some experiments, Tat protein was heat inactivated by incubation at 85°C for 30 min. Ficoll-Paque for the preparation of peripheral blood lymphocytes (PBL) was obtained from Pharmacia (Uppsala, Sweden). Neutralizing anti-TNF-␣ antibody and recombinant human IL-2 and IP-10 were obtained from R&D Systems (Minneapolis, Minn.).
Cell culture. Human CRT-MG astroglioma cells were maintained in RPMI medium with 2 mM L-glutamine, 100 U of penicillin per ml, 100 g of streptomycin per ml, and 10% heat-inactivated fetal bovine serum (FBS) as previously described (47) . Human primary adult astrocytes were obtained from biopsy material of patients undergoing surgery to treat intractable epilepsy as described earlier (4) . These cells are 95% positive for glial fibrillary acidic protein expression. For passage of CRT-MG cells and human primary astrocytes, medium was removed and cells were disloged by trypsinization (0.05% trypsin).
PBL were isolated from healthy donors by Ficoll-Paque density gradient centrifugation, followed by plastic panning to remove macrophages, and were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 U of penicillin per ml, and 100 g of streptomycin per ml. PBL were stimulated with phytohemagglutinin (5 g/ml; Boehringer GmbH, Mannheim, Germany) and 100 U of human IL-2 per ml for 10 days.
RNA isolation and RPA. Incubation of human primary adult astrocytes and CRT-MG cells with Tat 72aa for RNase protection assays (RPA) was performed in 75-ml flasks containing 2 ml of RPMI medium, 2 mM L-glutamine, 100 U of penicillin per ml, and 100 g of streptomycin per ml, either in the absence or in the presence of 10% FBS. Stimulation in the absence or presence of serum revealed the same results (data not shown). After addition of Tat 72aa protein, cells were incubated for the indicated times on a rocker at 37°C. Adherent cells were then rinsed once with ice-cold phosphate-buffered saline and dislodged by brief exposure to trypsin-EDTA (0.05% trypsin, 0.02% EDTA; Gibco BRL). Cells were washed twice with ice-cold phosphate-buffered saline, pelleted, and frozen for subsequent RNA extraction. Cell pellets were lysed, and RNA was extracted with guanidinium isothiocyanate and phenol and precipitated with ethanol as described previously (60) . A linearized human chemokine multiprobe set (hCK-5; catalog no. 45035P; Pharmingen, San Diego, Calif.) was transcribed with T7 RNA polymerase, resulting in 10 antisense RNA probes of different lengths for lymphotactin, RANTES, IP-10, MIP-1␤, MIP-1␣, MCP-1, IL-8, I-309, and L32. As an internal control standard, a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe is provided. RPA were performed as previously described (47) . Ten to 15 g of total RNA was hybridized with dUTP-labeled hCK-5 riboprobes and separated on a denaturing (8 M urea) 5% polyacrylamide gel. For quantification of protected RNA fragments, the gels were analyzed using a PhosphorImager and ImageQuant software (Molecular Dynamics, Sunnyvale, Calif.). Values for each chemokine mRNA were normalized to GAPDH mRNA expression for each experimental condition as previously described (47) .
ELISA. To determine secretion of chemokines by Tat-activated primary astrocytes and astroglioma cells, enzyme-linked immunosorbent assays (ELISAs) were performed. Primary astrocytes or CRT-MG cells (3 ϫ 10 5 ) were plated in six-well plates, incubated for 24 h, and then stimulated with Tat 72aa for 24 h. All experiments were done in the absence of serum. Expression of MCP-1 and IL-8 in the supernatants was quantitated using a dual-antibody solid-phase ELISA (Biosource International, Camarillo, Calif.) in accordance with the manufacturer's instructions, as previously described (47) . The dual-antibody solid-phase ELISA used for IP-10 was based on anti-human IP-10 antibodies (catalog no. 266-IP and BAF266; R&D Systems), and the instructions of the manufacturer were followed. Each supernatant sample was analyzed in duplicate.
Migration assays. Migration assays were performed using 24-well Transwell plates (Costar). One milliliter of conditioned medium from unstimulated astrocytes or astrocytes stimulated for 24 h with HIV-1 Tat 72aa was added to the lower chamber. IL-2-activated PBL (10 6 ) in 200 l of RPMI medium were placed in the upper chamber. Chambers were separated by a 3-m-pore-size polycarbonate membrane. The chambers were incubated for 4 h at 37°C in 5% CO 2 , and then the Transwell inserts were removed and 0.5 ϫ 10 5 fluorescein isothiocyanate-conjugated Calibrite-Beads (Becton Dickinson) were added as a standard. Cells were then transferred to tubes, and ratios of Calibrite-Beads to unstained, migrated cells were used to calculate the total number of migrated cells per well. To investigate the role of IP-10 in cell migration, 10 g of neutralizing anti-IP-10 antibody (catalog no. BAF266; R&D Systems) per ml or isotype-matched control antibody (10 g/ml) was added 30 min prior to the onset of the migration assay.
Statistical analysis. Levels of significance for comparisons between samples were determined using Student's t-test distribution. then multiprobe RPA was used to analyze chemokine expression. MCP-1 and IL-8 mRNAs were constitutively expressed at low levels in primary astrocytes, whereas there was no basal expression of any of the other chemokines (Fig. 1A, lane 2) . In response to Tat 72aa (1 nM), primary human astrocytes showed induction of mRNA for MCP-1, IL-8, and IP-10 (Fig. 1A, lane  3) . Increased expression of MCP-1, IL-8, and IP-10 mRNAs was observed when 10 nM Tat 72aa was used, while a higher concentration of Tat 72aa (100 nM) did not further enhance expression (Fig. 1A , lanes 4 and 5, and 1B, C, and D). Depending on the donor or the passage number of the primary astrocytes, the degree of chemokine mRNA induction after Tat 72aa treatment was variable (Table 1) . Nevertheless, a consistent pattern of chemokine mRNA induction in response to Tat 72aa stimulation was observed. CRT-MG astroglioma cells reacted in a fashion comparable to that of primary astrocytes. CRT-MG cells constitutively expressed small amounts of MCP-1 and IL-8 mRNAs (Fig. 2A, lane 2) . A Tat 72aa concentration of 0.5 nM stimulated MCP-1, IL-8, and IP-10 mRNA expression ( Fig. 2A, lane 4) . In a dose-dependent manner, Tat 72aa increased the expression of MCP-1, IL-8, and IP-10 mRNAs ( Fig. 2A, lanes 5 to 7) , reaching saturation between 10 and 50 nM (Fig. 2B, C, and D) . RANTES mRNA was found to be induced only at high concentrations of Tat 72aa in CRT-MG cells ( Fig. 2A, lanes 6 and 7) . The specificity of the Tat 72aa effect was confirmed by immune precipitation of Tat 72aa prior to stimulation of the cells, resulting in Ͼ70% abrogation of Tat 72aa -induced chemokine mRNA expression (data not shown).
RESULTS

Dose
Kinetics of chemokine mRNA induction by HIV-1 Tat 72aa in human astroglioma cells. Kinetic analysis of Tat 72aa induction of chemokines revealed differences in the pattern of induction time and stability. CRT-MG cells were incubated with Tat 72aa (50 nM) for various amounts of time (1 to 24 h), and then mRNA expression was detected by RPA. MCP-1 and IL-8 mRNAs were induced within the first hour after Tat 72aa stimulation (Fig. 3A, lane 3) . MCP-1 mRNA peaked at 6 h but was still elevated after 24 h (Fig. 3C) . IL-8 mRNA exhibited a biphasic pattern of expression; levels first peaked after 2 h, declined slightly, and then reached a second peak at 12 h (Fig.  3D) . Levels of IL-8 mRNA were still increased 24 h after stimulation (Fig. 3D) . IP-10 induction was delayed; IP-10 mRNA was first detectable 2 h after Tat 72aa stimulation, peaked at 12 h, and returned to basal levels 24 h after stimulation (Fig. 3B) .
As Tat has previously been described to stimulate TNF-␣ expression (10) , and TNF-␣, in turn, can induce expression of IL-8, MCP-1, and IP-10 in astrocytes (47), we wanted to exclude a possible influence of TNF-␣ produced by an autocrine mechanism. Therefore, CRT-MG cells were stimulated with 50 nM Tat 72aa in the absence or presence of neutralizing antihuman TNF-␣ antibody (5 g/ml). Under these conditions, Tat 72aa -mediated induction of IL-8, MCP-1, or IP-10 mRNA was not affected (data not shown), suggesting that endogenous production of TNF-␣ is not responsible for Tat 72aa -induced chemokine expression.
Secretion of chemokine protein after stimulation of primary astrocytes and astroglioma cells with HIV-1 Tat 72aa . To test whether Tat 72aa stimulation of astrocytes would lead not only to the induction of chemokine mRNA but also to the synthesis and secretion of the encoded chemokine proteins, primary human adult astrocytes and CRT-MG cells were stimulated with Tat 72aa and secretion of IL-8, IP-10, and MCP-1 was detected after 24 h using ELISA. All three chemokines were efficiently synthesized and secreted into the culture supernatants (Fig. 4) .
Capacity of supernatants from Tat 72aa -stimulated astrocytes to induce migration of PBL. To assess the functionality of the secreted chemokines, we performed migration assays with Transwell plates using PBL which consisted primarily of T cells (90% of the PBL used in the migration assays expressed the T-cell receptor, as assessed by fluorescence-activated cell sorter analysis). Within the 4-h time frame of the experiment, minimal migration of PBL was observed in response to supernatants from unstimulated astrocytes. In response to supernatants from Tat 72aa -stimulated CRT-MG cells, PBL exhibited greatly increased migratory activity (Fig. 5) . Interestingly, this activity was completely abrogated upon the addition of neu- I  2  14  183  5  30  II  6  3  10  12  III  4  23  5  17  III  5  11  4  17 a Cells were derived from three different patients (I to III) who underwent surgery to treat intractable epilepsy.
b Depending on availability, cells were assayed at different passages. c Primary human astrocytes were stimulated for 6 h with 100 nM Tat tralizing anti-IP-10 antibody to the supernatants of astrocytes stimulated with Tat 72aa , whereas a control antibody had no effect on migration. Supernatants from CRT-MG cells stimulated with heat-inactivated Tat did not cause migration. Migration also was not detected when Tat 72aa (50 nM) was used directly as a chemoattractant. In contrast, IP-10 (10 ng/ml) induced migration of PBL to a degree similar to that of supernatants from Tat 72aa -stimulated astrocytes (Fig. 5) . Comparable results were obtained by using supernatants from Tat 72aa -stimulated primary astrocytes (data not shown). These findings suggest that IP-10 in the supernatants from Tat 72aa -stimulated astrocytes is the major attractant for T cells.
Inhibition of Tat 72aa -induced chemokine expression by MEK and p38 MAPK inhibitors. We next examined the signal transduction pathways activated upon Tat 72aa that are involved in chemokine induction, focusing on the involvement of MAPKs in this response. MAPKs are activated by a variety of extracellular stimuli and can be divided into three major signal transduction cascades: the ERK1/2 MAPK pathway, involving mainly Ras, Raf, and MEK1/2; the JNK/SAPK pathway; and the p38 pathway. The ERK1/2 pathway is thought to be activated mainly by growth factors, whereas the JNK/SAPK pathway is activated by heat shock or inflammatory cytokines, as is the p38 pathway (for a review, see reference 12).
Using the highly specific MEK1/2 inhibitor UO126 and its negative control UO124, IL-8 mRNA induction by Tat was almost completely blocked at a UO126 concentration of 1 M while UO124 at 10 M had no inhibitory effect (Fig. 6C ).
UO126 also partially abrogated MCP-1 mRNA induction by Tat 72aa (Fig. 6B) , whereas IP-10 induction remained unaffected (Fig. 6A ). In accordance with these findings, we have determined that ERK1/2 is phosphorylated 20 min after stimulation with 50 nM Tat 72aa (data not shown). Using the p38-specific inhibitor SB202190 (negative control, SB202474), we demonstrate that increasing concentrations of SB202190 strongly inhibit the induction of IP-10 mRNA by Tat 72aa (Fig.  6D) , with modest inhibition of MCP-1 (Fig. 6E) or IL-8 (Fig.  6F) . SB202474 was without effect on IP-10, MCP-1, and IL-8 expression. These findings indicate that the MAPK pathway is of major importance in the signal transduction pathway activated by extracellular Tat 72aa . to the compromised systemic immune response, thereby potentially serving as vehicles by which infectious agents invade the brain. Chemokines are capable of participating in both syndromes, either by the recruitment of immune cells into the brain or by alteration of vital cellular functions. RANTES, SDF-1, and IP-10 exhibit the ability to recruit T cells (8, 9, 57, 63) , while MCP-1 and MIP-1 are major attractants for macrophages (19, 68) . SDF-1 also has the capacity to induce apoptosis in neurons (23, 27) . Therefore, it is of major importance to elucidate sources and stimulators of chemokine production in the CNS during the course of an HIV-1 infection as control of chemokine expression may be beneficial for HAD patients.
DISCUSSION
HIV-1-infected cells release the viral Tat protein, either by secretion or due to the cytopathic effect of the virus (16) . Externally applied Tat 72aa has been shown to be a potent inducer of different cellular genes; in various cell types, it is capable of stimulating expression of IL-6 (45, 56, 69), TNF (10, 55), IL-8 (25, 49) , and MCP-1 (13, 43, 67) . In this study, we demonstrated that primary human adult astrocytes and CRT-MG human astroglioma cells are stimulated by extracellularly applied Tat 72aa to express elevated levels of the CC chemokine MCP-1, as well as of the CXC chemokines IL-8 and IP-10. One nanomolar Tat 72aa was sufficient to induce significant levels of all three chemokine mRNAs in both primary astrocytes and CRT-MG astroglioma cells. The kinetics of mRNA induction after Tat 72aa stimulation differed for all three chemokines. MCP-1 and IL-8 mRNA induction was evident at 1 h, whereas IP-10 mRNA induction was not strongly detected until 4 h. MCP-1 mRNA induction peaked after 6 h, and MCP-1 mRNA was still present at elevated levels after 24 h. IP-10 mRNA peaked at 12 h but returned to basal levels after 24 h. IL-8 mRNA induction exhibited a first peak after 2 h and a second after 12 h. Due to the fast initial induction of the different chemokine mRNAs, these findings suggest that the initial mRNA induction is due only to the extracellularly applied Tat 72aa . As Tat has been reported to induce TNF-␣ in astrocytes (10) and, in turn, TNF-␣ is capable of inducing chemokine expression (47) , neutralizing anti-TNF-␣ antibody was added to the Tat-stimulated cultures and found to have no effect on chemokine induction. This supports the idea that Tat can directly stimulate chemokine expression. Nevertheless, we cannot exclude the possibility that secretion of other cytokines due to Tat 72aa stimulation activates chemokine expression in astrocytes in an autocrine fashion. The biphasic pattern of IL-8 mRNA expression suggests the involvement of other factors, possibly IL-1␤, at a later stage of the response (47) .
As induction of chemokines in astrocytes by different stimuli has been demonstrated to be dependent on the MAPK signaling pathway (38) and Tat has been demonstrated to be capable of activating the MAPK signaling pathway in glial cells (44), we investigated the involvement of the MAPK signaling pathway in Tat-mediated chemokine induction. Finding that ERK1/2 became phosphorylated after Tat 72aa stimulation (data not shown), UO126, a very potent and highly specific MEK1/2 inhibitor (18) , was utilized to demonstrate the involvement of the ERK pathway. We found that UO126 partially inhibited Tat 72aa -mediated induction of MCP-1 and abrogated the induction of IL-8 but had no effect on IP-10 mRNA induction. In contrast, SB202190, a specific inhibitor of p38 MAPK activation (37), efficiently suppressed IP-10 mRNA induction by Tat 72aa , while expression of MCP-1 and IL-8 mRNAs was affected less. These findings suggest that Tat activation of MCP-1 and IL-8 gene expression is only partially dependent on p38 MAPK activation, as even high concentrations of SB202190 could not completely suppress expression. Tat-mediated IL-8 gene regulation is stringently controlled by the ERK1/2 pathway, while IP-10 regulation by Tat 72aa exclusively involves the p38 MAPK pathway. Supernatants from Tat 72aa -stimulated astrocyte cultures exhibited a strong capacity to induce migration of IL-2-stimulated PBL, which was completely abrogated using neutralizing anti-IP-10 antibody. This finding is very interesting in the context of a recent publication in which Fontana and coworkers demonstrated that elevated IP-10 levels correlate with the degree of HAD and IP-10 is the main factor in the CSF to cause migration of T cells in HIV-1-infected patients (33) . Our findings suggest that astrocytes are a major source of IP-10 in the brains of HIV-1-infected patients. In this regard, the p38 MAPK signal transduction pathway would be an interesting target for pharmaceutical drugs to control IP-10 expression in the brains of HIV-1-infected patients. Other signaling pathways may be involved in Tat-mediated chemokine induction. We found that Tat 72aa induction of all three chemokine mRNAs could be abrogated by preincubation of the astrocytes with tolylsulfonyl phenylalanyl chloromethyl ketone (TPCK), a potent inhibitor of NF-B activation (data not shown). Involvement of NF-B has been described in the induction of IL-8 (49) and IP-10 (48) in other cell types using other stimuli and in astrocytes for the stimulation of TNF-␣ (10). Thus, further investigation is needed to definitely determine the involvement of NF-B in the induction of the monitored chemokines by Tat 72aa in astrocytes and possible cross talk with the MAPK signaling pathway.
Recent publications suggest that other T-cell attractants, such as RANTES, are increased in the CSF of HIV-1 patients (28), as well as MIP-1␣ and MIP-1␤ (58), two potent macrophage attractants. In our study, Tat 72aa did not lead to an increase in MIP-1␣ or MIP-1␤ expression in astrocytes and only a minor increase in RANTES production could be seen. An earlier study in our laboratory also demonstrated that MIP-1␣ and MIP-1␤ could not be induced in astrocytes by cytokines such as TNF-␣, IFN-␥, and IL-1␤ (47) . Therefore, these chemokines may be produced by cells in the CNS other than astrocytes, such as microglia and/or macrophages (42) .
The presence of elevated levels of IP-10 can be connected to the migration of T cells into the CNS. IP-10 has been shown to be increased not only in the brains of HIV-1-infected patients (33) and macaques with SIV encephalitis (54) but also in a variety of other diseases, all of which exhibit increased levels of activated T cells in the brain, such as Theiler's virus-mediated demyelination (24, 64) , experimental allergic encephalomyelitis (51), or multiple sclerosis (61) . A possible role for IL-8 in HAD is less obvious. Thus far, IL-8 has been reported to attract mainly neutrophils, which are absent in the brains of HIV-1-infected patients. Nevertheless, there is evidence that IL-8 is of major importance in the brain. IL-8 release into the CSF after brain injury is associated with blood-brain barrier dysfunction (6) and nerve growth factor production (34) . IL-8 is produced by astrocytes under acidosis (66) , by blood mononuclear cells after ischemic stroke (35) , and in neoplastic and infectious diseases of the human CNS (35) . Also, a recent publication suggests that IL-8 contributes to shear flow-resistant adhesion of macrophages to vascular endothelial cells (20) . In this context, IL-8 secreted by astrocytes may facilitate the extravasation of macrophages through the blood-brain barrier. Of interest is the finding that depletion of IL-8 by addition of neutralizing antibodies to astrocyte cultures renders astrocytes susceptible to Fas-mediated apoptosis (53) . Increased IL-8 expression in the brain could be a response to stress, promoting the survival of astrocytes. A better understanding of chemokine expression in the brain may therefore be of great interest not only for HAD therapy but also as a strategy to prevent opportunistic infections in the brain. 
